CancerDrs

Pancreatic Cancer clinical trials in Kentucky

19 actively recruiting pancreatic cancer trials at 11 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Kentucky:
  • University of Kentucky Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…

Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Kentucky:
  • Research Facility — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in Kentucky:
  • Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care — Edgewood, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…

Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Kentucky:
  • University of Kentucky Medical Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…

Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Kentucky:
  • Norton Cancer Institute /ID# 248903 — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05372614
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kentucky:
  • CommonSpirit Saint Joseph Hospital - Bardstown — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
  • Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
  • CommonSpirit Saint Joseph Hospital - Lexington — Lexington, Kentucky
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky:
  • Baptist Corbin — Corbin, Kentucky
  • Baptist Hardin — Elizabethtown, Kentucky
  • Baptist Lexington — Lexington, Kentucky
  • Baptist Paducah — Paducah, Kentucky
View on ClinicalTrials.gov →
Recruiting Academic/Other

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients …

Sponsor: University of Louisville
NCT ID: NCT02674100
Sites in Kentucky:
  • University of Louisville — Louisville, Kentucky
View on ClinicalTrials.gov →
Recruiting Industry

EXoPERT EMERALD Clinical Study

The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhance…

Sponsor: EXoPERT
NCT ID: NCT07186296
Sites in Kentucky:
  • Lexington VA Healthcare System — Lexington, Kentucky
  • KCTL — Louisville, Kentucky
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\*1/\*28) (heterozygotes) and usual UGT metab…

Sponsor: Reema A. Patel
NCT ID: NCT05391126
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27